Research progress on the mechanism of recurrence and metastasis of giant cell tumor of bone
Fan Mengke1,2, Wang Ling1,3, Ma Jiangtao1, Zhu Chao1, Zhang Qi1,2
1Orthopaedic Research Institute, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China; 2College of Integrated Traditional Chinese and Western Medicine, Hebei Medical University, Shijiazhuang 050051, China; 3Department of Bone Tumor, the Third Hospital of Hebei Medical University, Shijiazhuang 050051, China
摘要目的 总结骨巨细胞瘤(GCTB)复发转移机制的研究进展,以期为寻找新的诊治靶点提供必要的实验及理论依据。方法 在 PubMed、中国知网、万方数据和大医医学等数据库以“骨巨细胞瘤”“骨巨细胞瘤复发”“骨巨细胞瘤转移”和“giant cell tumor of bone”“recurrence of giant cell tumor of bone”“metastasis of giant cell tumor of bone”为中英文关键词,检索2001年1月—2018年12月国内外有关骨巨细胞瘤复发转移机制方面的相关文献资料,并进行汇总分析。结果 共检索到文献5 703篇,按纳入标准和排除标准最终纳入40篇文献,其中中文文献9篇和英文文献31篇。大量的研究证实RANK/RANKL信号通路、基质金属蛋白酶、细胞周期相关分子、肿瘤微环境细胞因子、组蛋白修饰、免疫细胞与相关分子等对GCTB的复发转移有促进作用。结论 GCTB较强的侵袭性及远处转移性导致治疗遭遇瓶颈,其复发转移机制至今仍不清楚,因此深入研究GCTB的复发转移机制,寻找新的治疗靶点非常关键。
Abstract：Objective To summarize the research progress of the mechanism of recurrence and metastasis of giant cell tumor of bone (GCTB).Methods Related literatures with the words “骨巨细胞瘤”“骨巨细胞瘤复发”“骨巨细胞瘤转移”, and “giant cell tumor of bone”“recurrence of giant cell tumor of bone”“metastasis of giant cell tumor of bone”on the mechanism of recurrence and metastasis of giant cell tumor of bone were searched and summarized in the database of PubMed, CNKI, Wanfang, and Dayi from January 2001 to December 2018.Results A total of 5 703 articles were retrieved, in which 40 articles were finally included according to the inclusion and exclusion criteria (9 Chinese articles and 31 English articles). A lot of researches confirmed that RANK/RANKL signaling pathway, matrix metalloproteinases, cell cycle related molecules, tumor microenvironment cytokines, histone modifications, immune cells and related molecules can promote the recurrence and metastasis of GCTB.Conclusions Strong recurrence and metastasis rate of GCTB, which mechanism remains unclear, has been a bottleneck stage in treatment. Therefore, it is critical to understand the mechanism of GCTB recurrence and metastasis to improve the treatment.
范梦科, 王玲, 马江涛, 朱超, 张奇. 骨巨细胞瘤复发转移机制的研究进展[J]. 中华解剖与临床杂志, 2020, 25(2): 208-212.
Fan Mengke, Wang Ling, Ma Jiangtao, Zhu Chao, Zhang Qi. Research progress on the mechanism of recurrence and metastasis of giant cell tumor of bone. Chinese Journal of Anatomy and Clinics, 2020, 25(2): 208-212.
Lin P, Lin N, Teng W, et al. Recurrence of giant cell tumor of the spine after resection: a report of 10 cases[J]. Orthop Surg, 2018, 10(2): 107-114. DOI:10.1111/os.12375.
[2]
Herr I, Sähr H, Zhao Z, et al. MiR-127 and miR-376a act as tumor suppressors by in vivo targeting of COA1 and PDIA6 in giant cell tumor of bone[J]. Cancer Lett, 2017, 409: 49-55. DOI:10.1016/j.canlet.2017.08.029.
[3]
Muheremu A, Niu X. Pulmonary metastasis of giant cell tumor of bones[J]. World J Surg Oncol, 2014,12:261. DOI:10.1186/1477-7819-12-261.
[4]
Won KY, Kalil RK, Kim YW, et al. RANK signalling in bone lesions with osteoclast-like giant cells[J]. Pathology, 2011, 43(4): 318-321. DOI:10.1097/PAT.0b013e3283463536.
[5]
Wu, PF, Tang, JY, Li KH. RANK pathway in giant cell tumor of bone:pathogenesis and therapeutic aspects[J]. Tumour Biol, 2015, 36(2): 495-501. DOI:10.1007/s13277-015-3094-y.
[6]
Matcuk GR Jr, Patel DB, Schein AJ, et al. Giant cell tumor:rapid recurrence after cessation of long-term denosumab therapy[J]. Skeletal Radiol, 2015, 44(7): 1027-1031. DOI:10.1007/s00256-015-2117-5.
[7]
Palmerini E, Chawla NS, Ferrari S, et al. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): for how long?[J]. Eur J Cancer, 2017, 76: 118-124. DOI:10.1016/j.ejca.2017.01.028.
[8]
Agarwal A, Larsen BT, Buadu LD, et al. Denosumab chemotherapy for recurrent giant-cell tumor of bone: a case report of neoadjuvant use enabling complete surgical resection[J]. Case Rep Oncol Med, 2013, 2013: 496351. DOI:10.1155/2013/496351.
[9]
Quattrini I, Pollino S, Pazzaglia L, et al. Prognostic role of nuclear factor/IB and bone remodeling proteins in metastatic giant cell tumor of bone:a retrospective study[J]. J Orthop Res, 2015, 33(8): 1205-1211. DOI:10.1002/jor.22873.
[10]
Ng PK, Tsui SK, Lau CP, et al. CCAAT/enhancer binding protein beta is up-regulated in giant cell tumor of bone and regulates RANKL expression[J]. J Cell Biochem, 2010, 110(2): 438-446. DOI:10.1002/jcb.22556.
[11]
Mak IW, Turcotte RE, Ghert M.Parathyroid hormone-related protein (PTHrP) modulates adhesion, migration and invasion in bone tumor cells[J]. Bone, 2013,55(1):198-207. DOI:10.1016/j.bone.2013.02.020.
[12]
Singh S, Singh M, Mak IW, et al. Investigation of FGFR2-ⅢC signaling via FGF-2 ligand for advancing GCT stromal cell differentiation[J]. PLoS One, 2012, 7(10): e46769. DOI:10.1371/journal.pone.0046769.
[13]
Zuo J, Jiang J, Dolce C, et al.Effects of basic fibroblast growth factor on osteoclasts and osteoclast-like cells[J]. Biochem Biophys Res Commun, 2004, 318(1): 162-167. DOI:10.1016/j.bbrc.2004.04.013.
[14]
毛庆, 卜海富, 桂斌捷. VEGF、Survivin在骨巨细胞瘤中的表达及其与预后的关系[J]. 安徽医科大学学报, 2007, 42(3): 323-325. DOI:10.3969/j.issn.1000-1492.2007.03.027. Mao Q, Pu FH, Gui BJ. The expression of VEGF and Survivin in giant cell tumor of bone and the correlation with prognosis[J]. Acta Universitatis medicinalis Anhui, 2007, 42(3): 323-325. DOI:10.3969/j.issn.1000-1492.2007.03.027.
[15]
Taylor RM, Kashima TG, Knowles HJ, et al. VEGF, FLT3 ligand, PlGF and HGF can substitute for M-CSF to induce human osteoclast formation: implications for giant cell tumour pathobiology[J]. Lab Invest, 2012, 92(10): 1398-1406. DOI:10.1038/labinvest.2012.108.
[16]
Wang T, Jiao J, Zhang H, et al. TGF-β induced PAR-1 expression promotes tumor progression and osteoclast differentiation in giant cell tumor of bone[J]. Int J Cancer, 2017, 141(8): 1630-1642. DOI:10.1002/ijc.30862.
[17]
Lou Z, Yang Y, Ren T, et al. Smad3 is the key to transforming growth factor-β1-induced osteoclast differentiation in giant cell tumor of bone[J]. Med Oncol, 2013, 30(3): 606. DOI:10.1007/s12032-013-0606-8.
[18]
Li B, Qian M, Cao H, et al. TGF-β2-induced ANGPTL4 expression promotes tumor progression and osteoclast differentiation in giant cell tumor of bone[J]. Oncotarget, 2017, 8(33): 54966-54977. DOI:10.18632/oncotarget.18629.
[19]
Ghert M, Simunovic N, Cowan RW, et al. Properties of the stromal cell in giant cell tumor of bone[J]. Clin Orthop Relat Res, 2007, 459: 8-13. DOI:10.1097/BLO.0b013e31804856a1.
[20]
Cowan RW, Mak IW, Colterjohn N, et al. Collagenase expression and activity in the stromal cells from giant cell tumour of bone[J]. Bone, 2009, 44(5): 865-871. DOI:10.1016/j.bone.2009.01.393.
[21]
Mak IW, Seidlitz EP, Cowan RW, et al. Evidence for the role of matrix metalloproteinase-13 in bone resorption by giant cell tumor of bone[J]. Hum Pathol, 2010, 41(9): 1320-1329. DOI:10.1016/j.humpath.2010.03.001.
喻盛杰, 倪海菜, 卜欣欣, 等. MMP-16与骨巨细胞瘤临床相关性的初步研究[J]. 现代生物医学进展, 2014, 14(28): 5427-5430, 5457. DOI:10.13241/j.cnki.pmb.2014.28.007. Yu SJ, Ni HC, Pu XX, et al. Preliminary research of clinical relevance of mmp-16 and gaint cell tumor[J]. Progess in Modern Biomedicine, 2014, 14(28): 5427-5430, 5457. DOI:10.13241/j.cnki.pmb.2014.28.007.
[24]
郭成学, 丁力, 王桂琴, 等. p27在骨巨细胞瘤中的表达及临床意义[J]. 中医正骨, 2006,18(1): 12-13. DOI:10.3969/j.issn.1001-6015.2006.01.005.Guo XC, Ding L, Wang GQ, et al. p27 protein expression in giant cell tumor of bone and its clinical significance[J]. The Journal of Traditional ChineseOrthopedics and Traumatology, 2006, 18(1): 12-13. DOI:10.3969/j.issn.1001-6015.2006.01.005.
[25]
李翀, 李海, 冯一中. 骨巨细胞瘤中Skp2、p27及E2F-1的表达及意义[J]. 临床与实验病理学杂志, 2011, 27(11): 1202-1205. DOI:10.3969/j.issn.1001-7399.2011.11.012. Li C, Li T, Weng ZY. The expression and significance of Skp2, p27 and E2F-1 in giant cell tumor of bone[J]. Chinese Journal of Clinical and Experimental Pathology, 2011, 27(11): 1202-1205. DOI:10.3969/j.issn.1001-7399.2011.11.012.
[26]
Yalcinkaya U, Ugras N, Kabul S, et al. Prognostic value of p53 protein expression in giant cell tumor of bone[J]. Pol J Pathol, 2015, 66(4): 389-396. DOI:10.5114/pjp.2015.57252.
[27]
Okubo T, Saito T, Mitomi H, et al. P53 mutations may be involved in malignant transformation of giant cell tumor of bone through interaction with GPX1[J]. Virchows Arch, 2013, 463(1): 67-77. DOI:10.1007/s00428-013-1435-z.
[28]
张浩, 于泓波, 李景先, 等. PCNA, Ki-67, p53在骨巨细胞瘤中的表达与预后的相关性[J]. 航空航天医学杂志, 2015, 26(2): 140-142. DOI:10.3969/j.issn.2095-1434.2015.02.005. Zhang H, Yu HB, Li JX, et al. Express of PCNA, Ki-67, p53 in giant cell tumor of bone and the prognostic relevance[J]. Journal of Aerospace Medicine, 2015, 26(2): 140-142. DOI:10.3969/j.issn.2095-1434.2015.02.005.
[29]
Behjati S, Tarpey PS, Presneau N, et al.Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone[J]. Nat Genet, 2013, 45(12): 1479-1482. DOI:10.1038/ng.2814.
[30]
Righi A, Mancini I, Gambarotti M, et al. Histone 3.3 mutations in giant cell tumor and giant cell-rich sarcomas of bone[J]. Hum Pathol, 2017, 68: 128-135. DOI:10.1016/j.humpath.2017.08.033.
[31]
Amary F, Berisha F, Ye H, et al. H3F3A (histone 3.3) G34W immunohistochemistry: a reliable marker defining benign and malignant giant cell tumor of bone[J]. Am J Surg Pathol, 2017, 41(8): 1059-1068. DOI:10.1097/PAS.0000000000000859.
[32]
Lim J, Park JH, Baude A, et al. The histone variant H3.3 G34W substitution in giant cell tumor of the bone link chromatin and RNA processing[J]. Sci Rep, 2017, 7(1): 13459. DOI:10.1038/s41598-017-13887-y.
[33]
Cowan RW, Ghert M, Singh G. T cells stimulate catabolic gene expression by the stromal cells from giant cell tumor of bone[J]. Biochem Biophys Res Commun, 2012, 419(4): 719-723. DOI:10.1016/j.bbrc.2012.02.086.
[34]
Al-Sukaini A, Hornicek FJ, Peacock ZS, et al. Immune surveillance plays a role in locally aggressive giant cell lesions of bone[J]. Clin Orthop Relat Res, 2017, 475(12): 3071-3081. DOI:10.1007/s11999-017-5451-1.
[35]
Sun XT, Yuan XW, Zhu HT, et al. Endothelial precursor cells promote angiogenesis in hepatocellular carcinoma[J]. World J Gastroenterol, 2012, 18(35): 4925-4933. DOI:10.3748/wjg.v18.i35.4925.
[36]
Zhou X, Liu XZ, Fan GT, et al. Expression of matrix metalloproteinase-9 and CD34 in giant cell tumor of bone[J]. Orthop Surg, 2016, 8(2): 220-225. DOI:10.1111/os.12250.
[37]
蔡颖, 冯一中, 张熔熔, 等. CD105、MMP-2和MMP-9在骨巨细胞瘤中的表达及意义[J]. 肿瘤防治研究, 2007, 34(7): 490-492, 546. DOI:10.3971/j.issn.1000-8578.2007.07.006. Cai Y, Feng YZ, Zhang RR, et al. Expression and significance of CD105, MMP-2 and MMP-9 in giant cell tumor of bone[J]. Cancer Research on Prevention and Treatment, 2007, 34(7): 490-492, 546. DOI:10.3971/j.issn.1000-8578.2007.07.006.
[38]
Zhang J, Dong J, Yang Z, et al. Expression of ezrin, CD44, and VEGF in giant cell tumor of bone and its significance[J]. World J Surg Oncol, 2015, 13: 168. DOI:10.1186/s12957-015-0579-5.
[39]
杨金三, 郭洪敏, 聂志奎, 等. CD44v5在骨巨细胞瘤中的表达及临床意义[J]. 济宁医学院学报, 2009, 32(2): 83-85. DOI:10.3969/j.issn.1000-9760.2009.02.003. Yang JS, Guo HM, Nie ZK, et al. Expression and clinical significance of CD44v5 in human giant cell tumor of bone[J]. Journal of Jining Medical University, 2009, 32(2): 83-85. DOI:10.3969/j.issn.1000-9760.2009.02.003.
[40]
毕乃贵, 王民, 王莹. CD147在骨巨细胞瘤中的表达及临床意义[J]. 现代肿瘤医学, 2007, 15(12): 1846-1848. DOI:10.3969/j.issn.1672-4992.2007.12.054. Bi NG, Wang M, Wang Y. Expression and clinical significance of CD147 in giant cell tumor of bone[J]. Journal of Modern Oncology, 2007,15(12): 1846-1848.DOI:10.3969/j.issn.1672-4992.2007.12.054.
2020, Vol. 25 
